MARY ANN GRAY - 04 Jun 2025 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role: Director
Signature: /s/ Keith Regnante, Attorney-in-Fact
Issuer symbol: KROS
Transactions as of: 04 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 06 Jun 2025, 16:15:10 UTC
Previous filing: 02 Jun 2025
Next filing: 18 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
GRAY MARY ANN	Director	C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON	/s/ Keith Regnante, Attorney-in-Fact	06 Jun 2025	0001261974

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KROS	Common Stock	Award	$0	+5,250		$0.000000	5,250	04 Jun 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KROS	Stock Option (right to buy)	Award	$0	+10,500		$0.000000	10,500	04 Jun 2025	Common Stock	10,500	$14.82	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
F2	The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.